Alnylam Cuts Amvuttra Sales Guidance as Second-Line Demand Normalizes, Hitting Stock on July 31, 2026 ALNY Alnylam Amvuttra ATTR-CM Demand (clinical) earnings guidance cut guidance revision Market Normalize (activity) pent-up demand Reaction revenue guidance Sales - occupational activity stock plunge TTR gene +
Valneva to cut up to 15% of jobs as reduced travel hits vaccine demand on May 14, 2026 Dukoral geopolitical factors guidance cut Ixchiq Ixiaro layoffs Lyme Disease operating costs restructuring travel Vaccines Valneva VLA15 workforce reduction +
Novo Nordisk Appoints New CEO and Reduces 2025 Sales Guidance on July 30, 2025 CEO Changing drug competition growth outlook guidance cut Leadership Maziar Mike Doustdar Nordisk Obesity Sales - occupational activity Transition Mutation +